Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BCT-100 in relapsed or refractory cancers of children and young adults
ISRCTN21727048Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of arginase-1 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma and 2 more, sponsored by University of Birmingham. Primary endpoints: Phase I recommended phase II dose based on safety, Phase I optimal biological dose based on arginine depletion and 1 more. Started Apr 2018; status: completed.
02
Drugs
arginase-1
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)neuroblastomaBone and soft tissue sarcomaglioma
Beyond the preview
Go deeper on ISRCTN21727048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21727048.